iRhythm Technologies, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Quentin S. Blackford
- Full Time Employees
- 2,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 699 8th Street San Francisco CA United States of America 94103
- IPO Date
- Oct 20, 2016
- CIK
- 0001388658
- Website
- irhythmtech.com
- Similar Companies
- Business
- iRhythm Technologies, Inc. iRhythm Technologies, Inc. (IRTC) is a leading digital healthcare company that develops and commercializes wearable biosensors and cloud-based platforms focused on cardiac arrhythmia detection and prediction. The company offers a comprehensive suite of ambulatory cardiac monitoring solutions through its Zio platform, including the Zio monitor for long-term continuous ECG monitoring up to 14 days, Zio XT for extended wear applications, Zio AT for real-time event monitoring without battery changes, and the recently submitted Zio MCT next-generation mobile cardiac telemetry device featuring a smaller form factor, 21-day wear period, and advanced detection algorithms; these services integrate AI-powered analytics verified by qualified cardiac technicians, patient symptom logging via the MyZio mobile app, and ZioSuite data management for physicians, achieving high diagnostic yield, 99% physician agreement on reports, and superior clinical outcomes compared to shorter-duration monitors. iRhythm Technologies, Inc. primarily serves cardiologists, primary care providers, and health systems in the United States, with expanding operations in Europe, the United Kingdom, Japan, and the Philippines from its headquarters at 699 8th Street, Suite 600, San Francisco, California, where it was founded in 2006. In recent developments, the company formed a strategic AI partnership with Lucem Health to enable early arrhythmia detection in high-risk populations such as those with type 2 diabetes, chronic kidney disease, COPD, and coronary artery disease; launched Zio long-term continuous monitoring services in Japan; reported record Q3 2025 revenue of $192.9 million, up 30.7% year-over-year, with raised full-year guidance to $735-740 million; published significant real-world studies in Heart Rhythm validating Zio performance and presented findings at AHA Scientific Sessions 2025 and other conferences demonstrating advantages in arrhythmia yield and healthcare cost reduction; and submitted a 510(k) filing to the FDA for Zio MCT while expanding value-based care partnerships across 18 active accounts.
iRhythm Holdings to Participate in Upcoming Investor Conferences
iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains
iRhythm Holdings, Inc. (IRTC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Wall Street Analysts Predict a 57.21% Upside in IRHYTHM HLDGS (IRTC): Here's What You Should Know
Why iRhythm Holdings, Inc. (IRTC) is a Top Momentum Stock for the Long-Term
IRTC Stock Up on Q1 Earnings & Revenue Beat, FY26 Outlook Raised
iRhythm Holdings, Inc. (IRTC) Q1 2026 Earnings Call Transcript
iRhythm Holdings, Inc. (IRTC) Reports Q1 Loss, Tops Revenue Estimates
iRhythm Holdings Announces First Quarter 2026 Financial Results
iRhythm Holdings to Present at the Bank of America Securities 2026 Health Care Conference
New Data Presented at HRS 2026 Show Short-Term Holter Monitoring Misses a Large Proportion of AF Recurrence Post-Ablation and Clinically Significant Arrhythmias in Pregnancy
iRhythm Holdings to Report First Quarter 2026 Financial Results on April 30, 2026
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Head-To-Head Survey: MSP Recovery (NASDAQ:MSPR) & iRhythm Technologies (NASDAQ:IRTC)
Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
Data presented at ACC.26 further demonstrate the benefits of iRhythm's Zio® ambulatory ECG portfolio across multiple patient populations as company launches new digital education platform
Assenagon Asset Management S.A. Grows Stock Position in iRhythm Technologies $IRTC
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
Cinctive Capital Management LP Takes $4.82 Million Position in iRhythm Technologies $IRTC